ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Effect of Anamorelin on Cachexia in Advanced NSCLC

Jennifer S. Temel, MD
Published Online:7:51 PM, Thu June 18, 2015

Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.